IL216723A - Annals of 4,2,1-Thiazolidine-3-On and their use in the treatment of cancer - Google Patents

Annals of 4,2,1-Thiazolidine-3-On and their use in the treatment of cancer

Info

Publication number
IL216723A
IL216723A IL216723A IL21672311A IL216723A IL 216723 A IL216723 A IL 216723A IL 216723 A IL216723 A IL 216723A IL 21672311 A IL21672311 A IL 21672311A IL 216723 A IL216723 A IL 216723A
Authority
IL
Israel
Prior art keywords
thiazolidin
cancer
derivatives
treatment
Prior art date
Application number
IL216723A
Other languages
English (en)
Hebrew (he)
Other versions
IL216723A0 (en
Original Assignee
Baltic Bio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baltic Bio Ab filed Critical Baltic Bio Ab
Publication of IL216723A0 publication Critical patent/IL216723A0/en
Publication of IL216723A publication Critical patent/IL216723A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL216723A 2009-07-08 2011-12-01 Annals of 4,2,1-Thiazolidine-3-On and their use in the treatment of cancer IL216723A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21373509P 2009-07-08 2009-07-08
PCT/GB2010/001315 WO2011004162A2 (en) 2009-07-08 2010-07-08 Compounds useful as medicaments

Publications (2)

Publication Number Publication Date
IL216723A0 IL216723A0 (en) 2012-03-01
IL216723A true IL216723A (en) 2017-09-28

Family

ID=43086401

Family Applications (1)

Application Number Title Priority Date Filing Date
IL216723A IL216723A (en) 2009-07-08 2011-12-01 Annals of 4,2,1-Thiazolidine-3-On and their use in the treatment of cancer

Country Status (24)

Country Link
US (2) US9162994B2 (enExample)
EP (1) EP2451794B1 (enExample)
JP (1) JP5982281B2 (enExample)
KR (1) KR101765957B1 (enExample)
CN (1) CN102596923B (enExample)
AU (1) AU2010270030B2 (enExample)
BR (1) BR112012000370B1 (enExample)
CA (1) CA2767291C (enExample)
DK (1) DK2451794T3 (enExample)
EA (1) EA026674B1 (enExample)
ES (1) ES2567753T3 (enExample)
HR (1) HRP20160353T1 (enExample)
HU (1) HUE027263T2 (enExample)
IL (1) IL216723A (enExample)
ME (1) ME02443B (enExample)
MX (1) MX337516B (enExample)
NZ (1) NZ597075A (enExample)
PL (1) PL2451794T3 (enExample)
RS (1) RS54718B1 (enExample)
SG (1) SG177558A1 (enExample)
SI (1) SI2451794T1 (enExample)
SM (1) SMT201600225B (enExample)
WO (1) WO2011004162A2 (enExample)
ZA (1) ZA201108901B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100931145B1 (ko) * 2008-07-04 2009-12-10 현대자동차주식회사 조정식 킥 다운 스위치의 조작기구
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
EP3571193B1 (en) 2017-01-23 2021-12-01 Cadent Therapeutics, Inc. Potassium channel modulators
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
MX2021004647A (es) 2018-10-22 2021-08-16 Novartis Ag Formas cristalinas de moduladores de los canales de potasio.
WO2020095010A1 (en) * 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
CN109879808B (zh) * 2019-03-05 2020-10-16 北京工业大学 一种含五元唑类杂环基查尔酮类衍生物及制备方法和医药用途
GB201910092D0 (en) 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
GB201910093D0 (en) 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) * 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
GB202112529D0 (en) 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
JP2026526085A (ja) 2023-07-20 2026-08-05 ベタゲノン アーベー 代謝非柔軟性により誘発される心筋症の治療方法
CN122421964A (zh) 2023-07-20 2026-07-17 塔吉农有限责任公司 使用双重ampk激活剂和线粒体解偶联剂调节血糖水平的方法
CN121925257A (zh) 2023-08-03 2026-04-24 塔吉农有限责任公司 用pdk抑制剂4-氯-n-(2-(4-氯苄基)-3-氧代-2,3-二氢-1,2,4-噻二唑-5-基)苯甲酰胺治疗癌症
WO2025252672A1 (en) 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093624A (en) 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
DE60129222T2 (de) 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
WO2006045581A1 (en) * 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
US20090156644A1 (en) 2005-07-21 2009-06-18 Jacob Westman Use of thiazole derivatives and analogues in the treatment of cancer
WO2008090356A1 (en) 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity

Also Published As

Publication number Publication date
BR112012000370A2 (pt) 2016-11-22
US20160128993A1 (en) 2016-05-12
AU2010270030A1 (en) 2012-01-12
WO2011004162A3 (en) 2011-03-03
JP2012532854A (ja) 2012-12-20
US9675596B2 (en) 2017-06-13
KR101765957B1 (ko) 2017-08-07
ES2567753T3 (es) 2016-04-26
JP5982281B2 (ja) 2016-08-31
ZA201108901B (en) 2017-08-30
SI2451794T1 (sl) 2016-05-31
US9162994B2 (en) 2015-10-20
HK1170485A1 (zh) 2013-03-01
CN102596923A (zh) 2012-07-18
IL216723A0 (en) 2012-03-01
BR112012000370B1 (pt) 2019-04-16
MX2012000441A (es) 2012-04-19
EA201200102A1 (ru) 2012-08-30
EP2451794B1 (en) 2016-01-27
KR20120054568A (ko) 2012-05-30
SG177558A1 (en) 2012-02-28
EP2451794A2 (en) 2012-05-16
CA2767291C (en) 2020-01-28
AU2010270030B2 (en) 2015-12-24
DK2451794T3 (en) 2016-03-14
SMT201600225B (it) 2016-08-31
RS54718B1 (sr) 2016-08-31
ME02443B (me) 2016-09-20
HUE027263T2 (en) 2016-10-28
CN102596923B (zh) 2015-04-29
PL2451794T3 (pl) 2016-07-29
MX337516B (es) 2016-03-09
EA026674B1 (ru) 2017-05-31
US20120183537A1 (en) 2012-07-19
NZ597075A (en) 2013-03-28
CA2767291A1 (en) 2011-01-13
HRP20160353T1 (hr) 2016-05-06
WO2011004162A2 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
IL216723A0 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
IL216283A0 (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
IL216599A (en) 4,1-Bi-Conjugated Phthalazine History, Pharmaceuticals Containing Them and Their Use in Cancer Treatment
IL223241A0 (en) Cysteamine derivatives and their use in the treatment of nash
ZA201106698B (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole and their use in cancer therapy
IL212960A (en) Sulfonamide derivatives, the vehicle containing them and their use in cancer treatment
IL220129A (en) History of benzamide, preparations containing them and their use in the treatment of cancer
GB201004137D0 (en) Phytocannabinoids in the treatment of cancer
IL213168A0 (en) 1,2,4-oxadiazole derivatives and their therapeutic use
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
ZA200907245B (en) Phthalazinone derivatives and their use as medicament to treat cancer
ZA201100210B (en) Pyridino-pyridinone derivatives,preparation thereof,and therapeutic use thereof
SI2173337T1 (sl) Fosfaplatini in njihova uporaba pri zdravljenju vrst raka, odpornih proti cisplatinu in karboplatinu
IL199911A0 (en) 3-cinnolinecarboxamide derivatives and their use for treating cancer
ZA201108106B (en) Use of phthalimide derivatives in the treatment of diseases
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
IL200966A0 (en) Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer
IL199966A0 (en) Azabicycloalkane derivatives, preparation thereof and use thereof in therapy
IL216717A0 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
HK1170238A (en) Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB0722338D0 (en) Novel use and treatment
PL387749A1 (pl) Nowe pochodne 4,5,6,7-tetrajodobenzimidazolu, sposób ich otrzymywania i zastosowanie medyczne

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed